Literature DB >> 26239536

Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque.

Josa M Frischer1, Stephen D Weigand2, Yong Guo3, Nilufer Kale3, Joseph E Parisi3,4, Istvan Pirko3, Jay Mandrekar2, Stephan Bramow5,6, Imke Metz7, Wolfgang Brück7, Hans Lassmann8, Claudia F Lucchinetti3.   

Abstract

OBJECTIVE: An extensive analysis of white matter plaques in a large sample of multiple sclerosis (MS) autopsies provides insights into the dynamic nature of MS pathology.
METHODS: One hundred twenty MS cases (1,220 tissue blocks) were included. Plaque types were classified according to demyelinating activity based on stringent criteria. Early active, late active, smoldering, inactive, and shadow plaques were distinguished. A total of 2,476 MS white matter plaques were identified. Plaque type distribution was analyzed in relation to clinical data.
RESULTS: Active plaques were most often found in early disease, whereas at later stages, smoldering, inactive, and shadow plaques predominated. The presence of early active plaques rapidly declined with disease duration. Plaque type distribution differed significantly by clinical course. The majority of plaques in acute monophasic and relapsing-remitting MS (RRMS) were active. Among secondary progressive MS (SPMS) cases with attacks, all plaque types could be distinguished including active plaques, in contrast to SPMS without attacks, in which inactive plaques predominated. Smoldering plaques were frequently and almost exclusively found in progressive MS. At 47 years of age, an equilibrium was observed between active and inactive plaques, whereas smoldering plaques began to peak. Men displayed a higher proportion of smoldering plaques.
INTERPRETATION: Disease duration, clinical course, age, and gender contribute to the dynamic nature of white matter MS pathology. Active MS plaques predominate in acute and early RRMS and are the likely substrate of clinical attacks. Progressive MS transitions to an accumulation of smoldering plaques characterized by microglial activation and slow expansion of pre-existing plaques. Whether current MS therapeutics impact this pathological driver of disease progression remains uncertain.
© 2015 American Neurological Association.

Entities:  

Mesh:

Year:  2015        PMID: 26239536      PMCID: PMC4623970          DOI: 10.1002/ana.24497

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  40 in total

1.  Immunopathology of secondary-progressive multiple sclerosis.

Authors:  J W Prineas; E E Kwon; E S Cho; L R Sharer; M H Barnett; E L Oleszak; B Hoffman; B P Morgan
Journal:  Ann Neurol       Date:  2001-11       Impact factor: 10.422

Review 2.  Pathology of demyelinating diseases.

Authors:  Bogdan F Gh Popescu; Claudia F Lucchinetti
Journal:  Annu Rev Pathol       Date:  2012       Impact factor: 23.472

3.  Demyelination versus remyelination in progressive multiple sclerosis.

Authors:  Stephan Bramow; Josa M Frischer; Hans Lassmann; Nils Koch-Henriksen; Claudia F Lucchinetti; Per S Sørensen; Henning Laursen
Journal:  Brain       Date:  2010-09-20       Impact factor: 13.501

4.  Homogeneity of active demyelinating lesions in established multiple sclerosis.

Authors:  Esther C W Breij; Bianca P Brink; Rob Veerhuis; Christa van den Berg; Rianka Vloet; Riqiang Yan; Christine D Dijkstra; Paul van der Valk; Lars Bö
Journal:  Ann Neurol       Date:  2008-01       Impact factor: 10.422

Review 5.  Taking ageing into account in remyelination-based therapies for multiple sclerosis.

Authors:  Julia M Rist; Robin J M Franklin
Journal:  J Neurol Sci       Date:  2008-06-09       Impact factor: 3.181

Review 6.  Pathology of multiple sclerosis: where do we stand?

Authors:  Bogdan F Gh Popescu; Istvan Pirko; Claudia F Lucchinetti
Journal:  Continuum (Minneap Minn)       Date:  2013-08

7.  Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance.

Authors:  Frederik Barkhof; Wolfgang Bruck; Corline J A De Groot; Elisabeth Bergers; Sandra Hulshof; Jeroen Geurts; Chris H Polman; Paul van der Valk
Journal:  Arch Neurol       Date:  2003-08

Review 8.  Progressive multiple sclerosis: pathology and pathogenesis.

Authors:  Hans Lassmann; Jack van Horssen; Don Mahad
Journal:  Nat Rev Neurol       Date:  2012-09-25       Impact factor: 42.937

9.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

10.  The relation between inflammation and neurodegeneration in multiple sclerosis brains.

Authors:  Josa M Frischer; Stephan Bramow; Assunta Dal-Bianco; Claudia F Lucchinetti; Helmut Rauschka; Manfred Schmidbauer; Henning Laursen; Per Soelberg Sorensen; Hans Lassmann
Journal:  Brain       Date:  2009-03-31       Impact factor: 13.501

View more
  166 in total

1.  Dark Rims: Novel Sequence Enhances Diagnostic Specificity in Multiple Sclerosis.

Authors:  J-M Tillema; S D Weigand; M Dayan; Y Shu; O H Kantarci; C F Lucchinetti; J D Port
Journal:  AJNR Am J Neuroradiol       Date:  2018-04-26       Impact factor: 3.825

Review 2.  Disease-Modifying Treatment in Progressive Multiple Sclerosis.

Authors:  John Robert Ciotti; Anne Haney Cross
Journal:  Curr Treat Options Neurol       Date:  2018-04-07       Impact factor: 3.598

3.  Persistent 7-tesla phase rim predicts poor outcome in new multiple sclerosis patient lesions.

Authors:  Martina Absinta; Pascal Sati; Matthew Schindler; Emily C Leibovitch; Joan Ohayon; Tianxia Wu; Alessandro Meani; Massimo Filippi; Steven Jacobson; Irene C M Cortese; Daniel S Reich
Journal:  J Clin Invest       Date:  2016-06-06       Impact factor: 14.808

4.  Quantitative susceptibility mapping identifies inflammation in a subset of chronic multiple sclerosis lesions.

Authors:  Ulrike W Kaunzner; Yeona Kang; Shun Zhang; Eric Morris; Yihao Yao; Sneha Pandya; Sandra M Hurtado Rua; Calvin Park; Kelly M Gillen; Thanh D Nguyen; Yi Wang; David Pitt; Susan A Gauthier
Journal:  Brain       Date:  2019-01-01       Impact factor: 13.501

5.  Joint assessment of brain and spinal cord motor tract damage in patients with early RRMS: predominant impact of spinal cord lesions on motor function.

Authors:  Raphaël Chouteau; Benoit Combès; Elise Bannier; Haykel Snoussi; Jean-Christophe Ferré; Christian Barillot; Gilles Edan; Paul Sauleau; Anne Kerbrat
Journal:  J Neurol       Date:  2019-06-07       Impact factor: 4.849

Review 6.  Multiple sclerosis.

Authors:  Massimo Filippi; Amit Bar-Or; Fredrik Piehl; Paolo Preziosa; Alessandra Solari; Sandra Vukusic; Maria A Rocca
Journal:  Nat Rev Dis Primers       Date:  2018-11-08       Impact factor: 52.329

7.  Aged hind-limb clasping experimental autoimmune encephalomyelitis models aspects of the neurodegenerative process seen in multiple sclerosis.

Authors:  Lindsay S Cahill; Monan Angela Zhang; Valeria Ramaglia; Heather Whetstone; Melika Pahlevan Sabbagh; Tae Joon Yi; Laura Woo; Thomas S Przybycien; Marina Moshkova; Fei Linda Zhao; Olga L Rojas; Josephine Gomes; Stefanie Kuerten; Jennifer L Gommerman; John G Sled; Shannon E Dunn
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-22       Impact factor: 11.205

8.  2-Arachidonoylglycerol Reduces Proteoglycans and Enhances Remyelination in a Progressive Model of Demyelination.

Authors:  Ana Feliú; Itziar Bonilla Del Río; Francisco Javier Carrillo-Salinas; Gloria Hernández-Torres; Leyre Mestre; Nagore Puente; Silvia Ortega-Gutiérrez; Maria L López-Rodríguez; Pedro Grandes; Miriam Mecha; Carmen Guaza
Journal:  J Neurosci       Date:  2017-07-27       Impact factor: 6.167

9.  Multimodal partial volume correction: Application to [11C]PIB PET/MRI myelin imaging in multiple sclerosis.

Authors:  Elisabetta Grecchi; Mattia Veronese; Benedetta Bodini; Daniel García-Lorenzo; Marco Battaglini; Bruno Stankoff; Federico E Turkheimer
Journal:  J Cereb Blood Flow Metab       Date:  2017-06-01       Impact factor: 6.200

10.  Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis.

Authors:  Antonia Valentina Genovese; Jesper Hagemeier; Niels Bergsland; Dejan Jakimovski; Michael G Dwyer; Deepa P Ramasamy; Alexis A Lizarraga; David Hojnacki; Channa Kolb; Bianca Weinstock-Guttman; Robert Zivadinov
Journal:  Radiology       Date:  2019-09-24       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.